🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction

Recruitingn/aAges 18 Years - anyAllShanghai Jiao Tong University Affiliated Sixth Pe…
NCT06766422 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Aneurysmal subarachnoid hemorrhage (SAH) is one of the critical diseases that severely threaten human health, with a clinical mortality rate reaching as high as 30%. Early diagnosis and intervention before rupture are considered key to improving the prognosis of aneurysmal SAH. With the widespread clinical application of non-invasive cerebrovascular imaging techniques, such as CTA and MRA, the detection rate of unruptured intracranial aneurysms (UIAs) has significantly increased. However, addressing the growing demand for clinical cerebrovascular imaging diagnostics raises the challenge of improving diagnostic accuracy while alleviating the workload of diagnostic physicians. Furthermore, considering that not all detected UIAs will rupture, it is crucial to accurately identify high-risk aneurysms prone to rupture to avoid unnecessary overtreatment, which could lead to significant socioeco

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years; 2. Preliminary diagnosis or symptoms indicating the presence or potential presence of a cerebral aneurysm; 3. Undergoing a non-contrast head MRA or contrast-enhanced head/neck CTA; 4. The patient or their legal representative is able and willing to sign an informed consent form. Exclusion Criteria: 1. Other intracranial vascular diseases: moyamoya disease, arteriovenous malformations, arteriovenous fistulas, arterial occlusions, and arterial dissections; 2. History of intracranial arterial interventions: stent placement, partial aneurysm coil treatment, etc.; 3. Severe allergy to contrast agents or absolute contraindications to iodine-based contrast agents; 4. Renal insufficiency with elevated serum creatinine (greater than twice the upper normal limit); 5. MRI contraindications: pacemakers, claustrophobia, etc.; 6. Diseases or conditions that affect the quality of CTA/MRA images; 7. Inability to complete the study due to psychiatric disorders, cognitive, or emotional disturbances. Note: The CTA sub-study does not include exclusion criterion 5; the MRA sub-study does not include exclusion criteria 3 and 4.
💊

What it tests

  • Not listed
📍

Where

1 site
Shanghai Sixth People's Hospital, Shanghai, 200023
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy